Published Aug 20, 2026
Boundless Bio, Inc. (BOLD): A Clinical-Stage Precision-Oncology Biotech Targeting Extrachromosomal-DNA Biology in ecDNA-Positive Tumors
In-depth research on BOLD covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,772 words17 min read
Read report